First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

Overview of attention for article published in Journal of Neurosurgery: Pediatrics, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 1 news outlet
twitter: 22 X users

facebook: 1 Facebook page

Readers on

mendeley: 65 Mendeley

So far, Altmetric has seen 26 X posts from 22 X users, with an upper bound of 69,982 followers.

@Kevin_McKernan @P_J_Buckhaults @RealJasonNelson Wait a while..the evidence will metastasize. https://t.co/aajSEvqHGA Keep messing with gmlab and we will see commensal onc cancer barcode into every mammal. https://t.co/vtbV8rvYo5

@jamiebuckner ONC201 is recruiting in Ohio for DIPG,. some have had prolonged survival, like this patient. https://t.co/NpdL3GIjiF. Those are 2 clinical trials I have heard some success.

RT @PedsSection: Progress in the battle against DIPG @TheJNS https://t.co/XHGRHPhCbp

RT @jallenphd: Activity in first DIPG patient treated with ONC201 just published online. ⁦@Oncoceutics⁩ https://t.co/6nVh67s918

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 22 additional X posts.